Bright Minds Biosciences (DRUG) Cash from Operations (2020 - 2026)

Bright Minds Biosciences has reported Cash from Operations for 7 years, with the latest figure at 6742308.75 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 498.9% year-over-year to 6742308.75; the trailing twelve-month figure through Mar 2026 stood at 20020782.59 (down 9572.95% YoY), and the FY2025 full-year result was 6315634.6, down 365.66% from the prior year.
• Cash from Operations for Q1 2026 stood at 6742308.75, down from 4170502.83 in the prior quarter.
• The five-year high for Cash from Operations was 2878012.84 in Q1 2022, with the low at 19203648.9 in Q3 2022.
• Historically, Cash from Operations has averaged 2233233.59 across 5 years, with a median of 597467.18 in 2024.
• The largest YoY upside for Cash from Operations was 182.9% in 2025 against a maximum downside of 4562.31% in 2025.
• Bright Minds Biosciences' Cash from Operations stood at 1962334.99 in 2022, then sank by 69.23% to 603852.11 in 2023, then surged by 77.16% to 1069760.66 in 2024, then sank by 489.85% to 4170502.83 in 2025, then slumped by 61.67% to 6742308.75 in 2026.
• The last three Cash from Operations figures came in at 6742308.75 (Q1 2026), 4170502.83 (Q4 2025), and 921379.0 (Q3 2025), per Business Quant data.